Indivior is cutting jobs and shrinking its office space. This is part of a new plan to save money. The company shared this in a filing with the US government this week. Indivior stated it aims to “simplify the company” by stopping unimportant tasks. This is the first step in its multi-year “Indivior Action Agenda.” The plan was announced in late July.
The cost-saving measures will include $16 million to $19 million for job cuts. Property exits and write-downs will cost $15 million to $22 million. Consulting and legal fees are expected to be $8 million to $9 million. In total, Indivior predicts $39 million to $50 million in costs for this restructuring. Most of these costs will hit in the latter half of the year.
Indivior did not say how many people would lose their jobs. Analysts at Jefferies believe savings will start appearing in the company’s profits in 2026.
Indivior wants its growth to match the US market for Sublocade. Sublocade treats opioid addiction. The market for this drug grew 19% from 2023 to 2024. Jefferies noted that daily Suboxone is still very profitable. Its earnings could rise if fewer generics enter the market. This could also happen if Teva does not release its generic version.
Analysts also said Indivior will keep a main research team. This team will support future drug testing if early results are good. However, the company does not see itself as a company focused on new drug pipelines. Indivior is testing two new drugs for opioid use disorder. These drugs are INDV-6001 and INDV-2000. Both are in Phase II testing.
Indivior is also looking at selling its opioid overdose spray, Opvee. This product has made little money outside of government deals. The company is also considering selling its business outside the US.
Indivior recently increased its 2025 revenue forecast. It now expects total revenue between $1.03 billion and $1.08 billion. Sublocade alone is expected to bring in $765 million to $785 million. This is an increase from previous estimates. The company also expects slower revenue drops for its Suboxone film product. This is due to stable pricing in the US market for generic versions. Opvee sales guidance remains at $10 million to $15 million.